In the news release, GeneNews Second Quarter 2018 Operating and Financial Results, issued 10-Aug-2018 by GeneNews Limited over Cision, we are advised by the company that the date of the Conference Call has changed to Wednesday, August 15, 8:30 AM ET. The complete, corrected release follows:
TORONTO, Aug. 10, 2018 /PRNewswire/ - GeneNews Limited ("GeneNews" or the "Company") (TSX:GEN) today announced that it will release its Second Quarter 2018 Operating and Financial results before markets open on Wednesday, August 15, 2018. GeneNews' Chairman and CEO, James R Howard-Tripp, will host a conference call at 8:30 am ET on August 15, to review the Operating and Financial results and discuss business developments for the period.
Second Quarter 2018 Results Conference Call Details:Date: August 15, 2018Time: 8:30 am ETLive Call: Local - Toronto (+1) 416 764 8609Toll Free - North America (+1) 888 390 0605Conference ID: 61579136Playback Phone Numbers: Local – Toronto (+1) 416 764 8677Toll Free – North America (+1) 888 390 0541Playback Passcode: 579136 #Playback Expiration Date: Tuesday, August 21, 2018 11:59 PM
The call will also be broadcast live and archived on the Company's website at www.GeneNews.com in the Investor's section.
About GeneNewsGeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. Our mission is to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with personalized clinical intelligence and actionable information to improve health outcomes through the early diagnosis of disease. Our Richmond, Virginia-based Innovative Diagnostic Laboratory clinical reference lab specializes in traditional and advanced clinical evidence-based blood testing that helps find, understand, and address cancer risk in patient populations. Currently, IDL offers risk assessment blood tests for four prevalent cancer types - colon, lung, prostate and breast. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information on GeneNews and IDL can be found at www.GeneNews.com and www.myinnovativelab.com, respectively.
Forward-Looking StatementsThis press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Corporation's actual events to differ materially from those projected herein. Investors should consult the Corporation's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Corporation disclaims any obligation to update these forward-looking statements, except as required by law.
Advertisement
GeneNews Second Quarter 2018 Operating and Financial Results
Conference Call – 8:30am Wednesday, August 15thAdvertisement
TORONTO, Aug. 10, 2018 /PRNewswire/ - GeneNews Limited ("GeneNews" or the "Company") (TSX:GEN) today announced that it will release its Second Quarter 2018 Operating and Financial results before markets open on Wednesday, August 15, 2018. GeneNews' Chairman and CEO, James R Howard-Tripp, will host a conference call at 8:30 am ET on August 15, to review the Operating and Financial results and discuss business developments for the period.
Second Quarter 2018 Results Conference Call Details:Date: August 15, 2018Time: 8:30 am ETLive Call: Local - Toronto (+1) 416 764 8609Toll Free - North America (+1) 888 390 0605Conference ID: 61579136Playback Phone Numbers: Local – Toronto (+1) 416 764 8677Toll Free – North America (+1) 888 390 0541Playback Passcode: 579136 #Playback Expiration Date: Tuesday, August 21, 2018 11:59 PM
The call will also be broadcast live and archived on the Company's website at www.GeneNews.com in the Investor's section.
About GeneNewsGeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. Our mission is to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with personalized clinical intelligence and actionable information to improve health outcomes through the early diagnosis of disease. Our Richmond, Virginia-based Innovative Diagnostic Laboratory clinical reference lab specializes in traditional and advanced clinical evidence-based blood testing that helps find, understand, and address cancer risk in patient populations. Currently, IDL offers risk assessment blood tests for four prevalent cancer types - colon, lung, prostate and breast. GeneNews' common shares trade on the Toronto Stock Exchange under the symbol 'GEN'. More information on GeneNews and IDL can be found at www.GeneNews.com and www.myinnovativelab.com, respectively.
Forward-Looking StatementsThis press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Corporation's actual events to differ materially from those projected herein. Investors should consult the Corporation's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Corporation disclaims any obligation to update these forward-looking statements, except as required by law.
View original content:http://www.prnewswire.com/news-releases/genenews-second-quarter-2018-operating-and-financial-results-300696512.html
SOURCE GeneNews Limited
